Mode
Text Size
Log in / Sign up
N/A Completed N=39

FREEZE-AFIB Post-Market Study

Source: ClinicalTrials.gov NCT05089877 ↗
Enrolled (actual)
39
Serious AEs
36.4%
Results posted
Jan 2025
Primary outcomePrimary: Freedom From Death, Stroke (Regardless of Level of Disability), Myocardial Infarction, and Major Bleeding Events. — 0 Participants

Summary

This study is proposed herein is to gather clinical data on the safety and performance of the CRYOF device.

Outcome Measures

OutcomeResultp-value
PRIMARY
Freedom From Death, Stroke (Regardless of Level of Disability), Myocardial Infarction, and Major Bleeding Events.
PRIMARY
Freedom From Any Documented AF, AFL or AT Lasting >30 Seconds in the Duration of the Last Follow-up Visit Off Antiarrhythmic Therapy (Except of AADs at Doses Not Exceeding Those Previously Failed
25
SECONDARY
Freedom From Any Documented AF, AFL, or AT Lasting >30 Seconds at the Last Follow-up Visit Regardless of Class I or III AADs
SECONDARY
Freedom From Any Documented AF, AFL, or AT Lasting >30 Seconds at the Last Follow-up Visit in the Absence of Class I or III AADs.
SECONDARY
Acute Procedural Success Defined as Documentation of Sinus Rhythm at the End of the Procedure.

Eligibility Criteria

Inclusion Criteria

  • Subject is greater than or equal to 18 years of age.
  • Subject has documented history of atrial fibrillation.
  • Subjects who received surgical ablation for their atrial fibrillation using CRYOF and on whom at least the following lesions were performed: Left and right pulmonary vein isolation, roof and floor lines, mitral annulus line and a connecting lesion from left atrial appendage to left pulmonary vein coronary sinus lesion and LAA exclusion , with a lesion duration of at least 2 minutes.
  • Stable subject that underwent non-emergent cardiac surgical procedure(s) on cardiopulmonary bypass including open-heart surgery for one or more of the following: mitral valve repair or replacement, aortic valve repair or replacement, tricuspid valve repair or replacement, or coronary artery bypass procedures, or atrial septal defect (ASD) repair
  • Left Ventricular Ejection Fraction ≥ 30% (determined by echocardiography or cardiac catheterization performed within 90 days of enrollment as documented in patient medical history).
  • Subject is willing and able to provide written informed consent.
  • Subject is willing and able to return for scheduled follow-up visits.

Exclusion Criteria

  • Stand-alone AF without indication(s) for concomitant CABG and/or valve surgery.
  • Previous left sided ablation procedures procedure.
  • Untreated atrial flutter and symptomatic ventricular arrythmia
  • Known carotid artery stenosis greater than 80% prior to index ablation procedure.
  • Prior history of ischemic stroke or hemorrhagic stroke
  • History of MI with ST elevation within 6 weeks prior to the index ablation
  • Documented AF duration of greater than 10 years.
  • Large left atrial size i.e., LA diameter >7 cm prior to the index ablation procedure.
  • Subjects with active systemic infection prior to index ablation procedure.
  • Subjects who had documented severe peripheral arterial occlusive disease defined as claudication with minimal exertion prior to the ablation procedure.
  • Subjects with history of renal failure requiring dialysis or hepatic failure prior to the ablation procedure.
  • A known drug and/or alcohol addiction.
  • Mental impairment or other conditions which may not allow the subject to understand the nature, significance, and scope of the study.
  • Subjects who are pregnant
  • Subjects who had preoperative need for mechanical circulatory support or intravenous inotropes.
  • Subjects who are on anti-arrhythmic drug therapy for the treatment of another arrhythmia.
  • Subjects in currently undergoing chemotherapy.
  • Subjects on long term treatment with oral or injected steroids (not including intermittent use of inhaled steroids for respiratory diseases).
  • Subjects who had known connective tissue disorders at the time of index ablation procedure
  • Subjects who had known hypertrophic obstructive cardiomyopathy at the time of index ablation procedure
  • Subjects with known cold agglutinin.
  • Subjects who had or tested positive for COVID-19
  • Subjects with bleeding disorders and/or inability to receive anticoagulation
  • Subjects undergoing aortic dissection surgery as index procedure.
  • Cardiac surgical re-intervention since the index cardiac surgery with concomitant AF ablation procedure
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05089877). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search